相关临床试验
41
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
24
58.5%
尚未招募
1
2.4%
招募中
6
14.6%
暂停
1
2.4%
终止
1
2.4%
Unknown
7
17.1%
撤回
1
2.4%
暂无批准数据
- A groundbreaking seven-year study published in Science Translational Medicine reveals that rheumatoid arthritis begins silently years before joint symptoms appear, with detectable immune system changes occurring in the pre-clinical stage. - Researchers at University of Colorado Anschutz identified specific biomarkers including anti-CCP antibodies that give individuals about a 30% risk of developing rheumatoid arthritis, affecting 1-2% of the population. - The study uncovered systematic inflammation, immune cell reprogramming, and joint-targeting signals in blood samples from at-risk individuals, providing multiple biological targets for early intervention and prevention strategies. - A separate clinical trial found that hydroxychloroquine did not prevent rheumatoid arthritis in high-risk individuals, helping researchers rule out this potential preventive treatment approach.
- A phase 2 trial demonstrated that 0.5 mg/kg antithymocyte globulin (ATG) preserves beta-cell function as effectively as the standard 2.5 mg/kg dose in newly diagnosed type 1 diabetes patients. - The lower dose significantly reduced adverse events, with cytokine release syndrome occurring in 24% versus 33% of patients and serum sickness in 32% versus 82% compared to the higher dose. - The adaptive trial design successfully identified the minimum effective dose while confirming safety in children as young as 5 years old. - The 0.5 mg/kg dose can be administered as a single-day infusion rather than requiring two days, offering practical advantages for clinical implementation.
